ANIX - התחייבויות לטווח ארוך של החברה Anixa Biosciences

Anixa Biosciences, Inc. (ANIX) is diversifying its women's health research by implementing AI diagnostics to minimize scientific risks. The company's revenue will be based on the market launch of CAR-T therapies and vaccines for ovarian and breast cancer. Meanwhile, long-term debt stands at 0.00, and the lack of stable cash flow is offset by grants. This price action on GURU.Markets illustrates the asset's current trend.

Assessing the resilience of Anixa Biosciences, Inc. (ANIX) to market downturns requires an analysis of its liability structure. The specifics of developing cancer vaccines without commercial sales create a high business dependency on external financing. The dynamics of the company's long-term borrowings reflect the volume of loans with maturities exceeding one year, measuring management's ability to raise capital for prolonged research. An increase in this indicator signals an expansion of investment leverage, thereby increasing financial risks during recessionary periods.